Novasep, a supplier of services and technologies for the life sciences industry, has announced a €5.1m ($5.6m) investment to expand its production capacity for HPAPIs at its Le Mans, France site.
The investment involves the addition of a chemical synthesis workshop for HPAPIs which will be commissioned in late 2023 and will add a further 10 full-time jobs. Through optimisations to its manufacturing processes, the company says this workshop will offer production solutions with reduced environmental impact.
This investment is aimed to support the company’s growth in the ADC market. With more than 15 years of experience in the field of ADCs, the company says its Le Mans site is recognised for its expertise in offering integrated solutions to produce ADC payloads and bioconjugation.
Rachel De Luca, Director of the Le Mans site explains: “The production at Le Mans site offers unparalleled flexibility to produce ADC payloads at different scales and in complete safety. We are increasing our production capacity to support the development of tomorrow's cancer drugs with agility, while enhancing the robustness of the supply chain of the commercial products of our historical customers.”
